Drug discovery and development company Redx Pharma (REDX), announced on Tuesday that Innovate UK was awarded a grant to fund the development of its biomarker project aiming to accelerate therapeutics for idiopathic pulmonary fibrosis.
The £515,595 grant was awarded to both Redx Pharma and Medicines Discovery Catapult who are leading the project.
The collaboration will enable a preclinical assessment, as well as informing a clinical development strategy for Redx’s Porcupine (RXC006) and ROCK2 inhibitors which aim to enter the clinic by 2021.
A multimodal approach will be undertaken by MDC to investigate novel biomarker signatures to characterise disease and treatment response.
The project, which is funded by Innovate UK, aims to accelerate the assessment of novel therapeutics for life-threatening fibrotic lung conditions which, amongst other fibrotic diseases, have a high unmet medical need.
Fibrotic diseases lack new therapies due to lack of translation between animal models and human disease -- additionally, robust biomarker strategies that can aid assessment in patients do not exist at present.
Redx’s project is working to validate and develop new biomarkers which are expected to assist a pipeline of new therapies for IPF, improving the likelihood of clinical success.
"This partnership with Redx will allow the development of a robust portfolio of biomarkers for IPF and the progression of anti-fibrotic therapies in a faster and better-informed way,” added Chief Scientific Officer of Medicines Discovery Catapult, Dr Peter Simpson.
Follow News & Updates from Nostra Terra here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
SP Angel research note on commodities and miners, featuring: Ferro-Alloy Resources Limited (FAR LN) – Fall in vanadium pentoxide price prompts management to look for new funding Resolute Mining (RSG LN) – Bibiani review Sirius Minerals (SXX LN) – A Siriusly sorry Christmas Carol Vast Resources* (VAST LN) 0.29p, Mkt Cap £29m – Exposure to copper and rough diamonds in Romania and Zimbabwe
Colin Bird Executive Chairman of Xtract Resources (XTR) talks about the Alluvial Collaboration Agreement with Nexus and provides a general update Russ Mould, Investment Director at stockbroker AJ Bell talks about: the Election Result, Macro and UK stocks Alan Green talks about 4 stocks
Mammoth Biosciences is a US-based biotech company that developed the world's first CRISPR-based detection platform capable of sensing any biomarker or disease with DNA/RNA backed by investors that include Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos, along with Tim Cook, Brook Byers, Bob Nelsen, and Jeff Huber.
“It has given us substantial financial flexibility at a highly competitive rate of interest in the last three years as we have successfully carried out our multi-well Niger drilling campaign and completed the Seven Energy transaction."
Tim McCarthy, Chairman of ImmuPharma (IMM) discusses the deal with US-based Avion Pharmaceuticals, the agreement with Lanstead Capital and what the future holds for ImmuPharma regarding new trial design as well as anticipated upcoming milestones.
The hedge fund owned by the billionaire investor and anti-Brexit donor George Soros has made a £16m bet against shares in the owner of the Daily Mail newspaper, Ocado has said its product range will be 50% bigger and offer lower prices and better quality products when it switches from Waitrose to Marks & Spencer next year,
SPAngel research note on commodities and miners, featuring: Base Resources (BSE LN) – Toliara DFS confirms PFS estimates Premier African Minerals* (PREM LN) – Fundraising Resolute Mining (RSG LN) – Drilling results from Tabakoroni
United’s Chief Executive, Brian Larkin, acknowledged the completion of the sale as proof of the group’s ability to manage their portfolio in a way which “delivers tangible returns for shareholders.”